

June 4, 2015



Navidea to Report Manocept™ Results in Kaposi's Sarcoma at the International Workshop on KSHV and Related Agents

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) and its subsidiary, Macrophage Therapeutics, Inc., today announced that four presentations of Manocept™ data from Kaposi's Sarcoma (KS) studies are scheduled at the 18th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents in Hollywood, Florida from June 30 - July 3, 2015. This research highlights a very likely new approach to the origin of KS supported by preclinical and clinical imaging studies. In addition, data will be presented demonstrating the therapeutic potential for Manocept therapeutic conjugates. MT1001 is a proprietary agent designed to target cells expressing the mannose receptor (CD206) and destroy the cell and its contents. Data will be presented demonstrating MT1001's ability to target KS and KS tumor-associated macrophages by selectively binding to CD206. Details of the presentations are listed below.

Poster Session:

Date: July 1, 2015

Title: In Vivo Localization and Potential for Therapeutic Targeting of Kaposi's Sarcoma (KS) With A Novel CD206 Localizing Agent

Authors: M McGrath^{a,b*}, J Zhang^a, T Maurer^a, S Behr^a, B Abbruzzese^c, J Sanders^c, P Braccia^b, FO Cope^c (*Presenter)

^aUniv of California-San Francisco; ^bAIDS & Cancer Specimen Resource, SFGH ^c Navidea/Macrophage Therapeutics

Poster Session:

Date: July 1, 2015

Title: Imaging and Therapeutic Potential for Kaposi's Sarcoma (KS) In Non-Cutaneous Foci with a Novel CD206 Localizing Agent

Authors: B Abbruzzese^{a*}, FO Cope^a, J Zhang^b, T Maurer^b, S Behr^b, J Sanders^a, P Bracci^{b,c}, M McGrath^{b,c} (*Presenter)

^aNavidea/Macrophage Therapeutics; ^bUniv of California-San Francisco; ^cAIDS & Cancer Specimen Resource, SFGH

**Poster
Session:**

Date: July 1, 2015

Title: Kaposi's Sarcoma (KS) is a Macrophage (MO) Tumor Resulting from a Fusion CD206+MOs and Lymphatic Endothelium

Authors: FO Cope^{a*}, J Zhang^b, T Maurer^b, B Abbruzzese^a, J Sanders^a, S Behr^b, P Bracci^{b,c}, M McGrath^{b,c} (*Presenter)

^aNavidea/Macrophage Therapeutics; ^bUniv of California-San Francisco; ^cAIDS & Cancer Specimen Resource, SFGH

**Oral
Session:** Translational Studies. KSHV Malignancies Associated with HIV/AIDS

Date: July 2, 2015

Title: Manocept, a Novel CD206 Targeting Agent for Potential Use in Treatment of Kaposi's Sarcoma

Authors: Rongzhen Zhang^a, Frederick O. Cope^b, Joshua Walker^c, Ken Williams^c, Ekaterina Maidji^a, Cheryl Stoddart^a, Paige M. Bracci^a, Michael S. McGrath^{a*} (*Presenter)

^aUniversity of California San Francisco; ^bNavidea/Macrophage Therapeutics; ^cBoston College

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea's first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company's pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements within the meaning of the Act. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof.

Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20150604006087/en/>

Navidea Biopharmaceuticals

Investors

Tom Baker, 617-532-0624

tbaker@navidea.com

or

Media

Sharon Correia, 978-655-2686

Associate Director, Corporate Communications

Source: Navidea Biopharmaceuticals, Inc.